A patient centric company Driven by Science

Dammam Pharma Launches EframXR

 

On the 10th of October 2017, Dammam Pharma sales and marketing team had the launch meeting for  efram  in Holiday Inn Riyadh

 

sales team

 

 

 

 

  • efram(Levetiracetam) is the first extended release antiepileptic in Saudi Arabia, it is a broad spectrum antiepileptic drug that binds to synaptic vesicle protein SV2A, used as adjunct therapy in the treatment of partial-onset seizures in patients with epilepsy.

  • efram(Levetiracetam extended release)  in the form of film coated tablets,  is developed to provide the convenience of once-daily dosing and safety/efficacy ratio benefits.

  • efram(Levetiracetam extended release)  mechanism of action is to target high-voltage N-type calcium channels as well as the synaptic vesicle protein 2A ( SV2A) .

  • efram(Levetiracetam extended release)  is marketed in 500 and 750 mg. forms.